Additional studies regarding the effect of Angiopoietin/Tie2 mediators on TF expression in EVs are warranted to confirm our findings, and to identify additional therapeutic targets that regulate immunothrombosis in COVID-19 and other viral respiratory diseases. The gene discussed is TF; the disease is COVID-19.